Spots Global Cancer Trial Database for ureter
Every month we try and update this database with for ureter cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00805129 | Bladder Cancer Metastatic Tran... | Everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT01551030 | Metastatic Tran... | Buparlisib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | NCT00588666 | Myeloproliferat... Urothelial Carc... Cancer | Bevacizumab Carboplatin Gemcitabine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00805129 | Bladder Cancer Metastatic Tran... | Everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Genotype-Phenotype Urothelial Cancer Registry | NCT00902590 | Urothelial Canc... Renal Pelvis Ca... Ureter Cancer Bladder Cancer | saliva sample a... saliva sample, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Genotype-Phenotype Urothelial Cancer Registry | NCT00902590 | Urothelial Canc... Renal Pelvis Ca... Ureter Cancer Bladder Cancer | saliva sample a... saliva sample, ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03170960 | Urothelial Carc... Renal Cell Carc... Non-Small Cell ... Castration-resi... Triple Negative... Ovarian Cancer Endometrial Can... Hepatocellular ... Gastric Cancer Gastroesophagea... Colorectal Canc... Head and Neck C... Differentiated ... Lower Esophagea... | cabozantinib atezolizumab cabozantinib cabozantinib | 18 Years - | Exelixis | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Efficacy and Safety of UGN-101 in Recurrent Patients | NCT04006691 | Carcinoma Transitional Ce... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
